The New England journal of medicine
-
To the Editor: Kelley and Morrison (Aug. 20 issue)(1) describe the changes in palliative care over the past decade and its distinct meaning vis-à-vis hospice care in the United States and, increasingly, most other countries. Unfortunately, the category of "most countries" does not include many countries in Asia, where attitudes and practices vary widely according to regional, economic, cultural, and religious differences and differences in legal systems.(2) Neither does this category include Iran, a nation of more than 75 million people in which medical science is advanced; sophisticated therapies such as kidney, heart, and lung transplantation are available; and investigational . . .
-
Randomized Controlled Trial Multicenter Study Comparative Study
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. ⋯ Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).